Free Trial
NASDAQ:TMDX

TransMedics Group (TMDX) Stock Price, News & Analysis

TransMedics Group logo
$114.96 -1.76 (-1.51%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$115.46 +0.50 (+0.43%)
As of 08/29/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TransMedics Group Stock (NASDAQ:TMDX)

Key Stats

Today's Range
$112.82
$117.05
50-Day Range
$103.61
$134.01
52-Week Range
$55.00
$172.78
Volume
665,581 shs
Average Volume
998,422 shs
Market Capitalization
$3.92 billion
P/E Ratio
59.57
Dividend Yield
N/A
Price Target
$123.00
Consensus Rating
Moderate Buy

Company Overview

TransMedics Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

TMDX MarketRank™: 

TransMedics Group scored higher than 66% of companies evaluated by MarketBeat, and ranked 348th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    TransMedics Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about TransMedics Group's stock forecast and price target.
  • Earnings Growth

    Earnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TransMedics Group is 59.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.86.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TransMedics Group is 59.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.27.

  • Price to Book Value per Share Ratio

    TransMedics Group has a P/B Ratio of 12.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about TransMedics Group's valuation and earnings.
  • Percentage of Shares Shorted

    24.19% of the float of TransMedics Group has been sold short.
  • Short Interest Ratio / Days to Cover

    TransMedics Group has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in TransMedics Group has recently decreased by 4.12%, indicating that investor sentiment is improving.
  • Dividend Yield

    TransMedics Group does not currently pay a dividend.

  • Dividend Growth

    TransMedics Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.19% of the float of TransMedics Group has been sold short.
  • Short Interest Ratio / Days to Cover

    TransMedics Group has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in TransMedics Group has recently decreased by 4.12%, indicating that investor sentiment is improving.
  • News Sentiment

    TransMedics Group has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for TransMedics Group this week, compared to 13 articles on an average week.
  • Search Interest

    24 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $95,903.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of TransMedics Group is held by insiders.

  • Percentage Held by Institutions

    99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about TransMedics Group's insider trading history.
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TMDX Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Headlines

TMDX Stock Analysis - Frequently Asked Questions

TransMedics Group's stock was trading at $62.35 on January 1st, 2025. Since then, TMDX shares have increased by 84.4% and is now trading at $114.96.

TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings data on Wednesday, July, 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The business's quarterly revenue was up 37.7% compared to the same quarter last year.
Read the conference call transcript
.

TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

Top institutional investors of TransMedics Group include Geode Capital Management LLC (2.36%), Hood River Capital Management LLC (1.99%), Eventide Asset Management LLC (1.61%) and Marshall Wace LLP (1.60%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, Anil P Ranganath, David Weill, Edward M Basile, Laura Damme and Stephanie Lovell.
View institutional ownership trends
.

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
7/30/2025
Today
8/30/2025
Next Earnings (Estimated)
10/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TMDX
CIK
1756262
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

High Price Target
$150.00
Low Price Target
$75.00
Potential Upside/Downside
+7.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.93
Trailing P/E Ratio
59.57
Forward P/E Ratio
114.96
P/E Growth
N/A
Net Income
$35.46 million
Net Margins
13.49%
Pretax Margin
13.95%
Return on Equity
28.02%
Return on Assets
8.64%

Debt

Debt-to-Equity Ratio
1.61
Current Ratio
9.86
Quick Ratio
9.17

Sales & Book Value

Annual Sales
$441.54 million
Price / Sales
8.88
Cash Flow
$1.65 per share
Price / Cash Flow
69.87
Book Value
$9.33 per share
Price / Book
12.32

Miscellaneous

Outstanding Shares
34,090,000
Free Float
31,704,000
Market Cap
$3.92 billion
Optionable
Optionable
Beta
2.09

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:TMDX) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners